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Introduction
The most common contemporary depiction of the
immune response is an early innate response, mounted by
myeloid cells, followed by a delayed adaptive lymphoid
responses mounted by lymphocytes. This depiction is
based on myriad compelling data sets and has made
powerful predictions with biological and clinical relevance.
Nonetheless, it seems incomplete. Thus, there are lympho-
cytes that respond very rapidly, commonly to self-encoded
molecules over-expressed by dysregulated and/or trans-
formed tissues and cells. The evidence for such “lymphoid
stress-surveillance” by gamma delta T cells has been pro-
vided by animal models, and supports ongoing clinical
investigations of the potential host-protective role of
gamma delta T cells in cancer.
Aim
To determine whether aminobisphosphonate treatments
with and without cytokines activate gamma delta T cells
in patients, and to determine whether any such activa-
tion is safe and/or efficacious.
Patients and methods
The phenotype and functional potentials of gamma delta
T cells have been monitored in a spectrum of patients
receiving zoledronate (zometa), while the activation of
gamma delta T cells in situ was attempted in a small
two arm trial carcinoma patients, using zoledronate with
and without interleukin-2.
Results
The most consistent response appears to be an upregu-
lation of an activating receptor, NKG2D, which can
mediate the functional response to transformed cells. In
the small two arm trial in prostate and breast cancer,
there were good indicators of safety and functional acti-
vation, including the consistent upregulation of cytolyitc
mediators and interferon-gamma. However, cell exhaus-
tion proved to be a concern. This provoked the idea of
coupling gamma delta cell activation in vivo with adop-
tive cell transfer, studies of which are now ongoing, and
will be presented.
Conclusions
The lymphoid stress-surveillance responsiveness of
gamma delta T cells has many biological characteristics
desired of cancer immunotherapy. Ongoing experiments
in several countries collectively show good safety and
promising results. Moreover, there is the potential for
such treatment to strongly synergise with chemotherapy.
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